Antibody Discovery Market Size, Growth, Share & Trends Analysis
Report Code
PH 9491
Published in
Sep, 2025, By MarketsandMarkets™
Antibody Discovery Services Market by Type (Target Identification, Antibody Engineering (Technology (Hybridoma, Phage Display, Single Cell)), Immunization), Host (Mouse, Rat, Rabbit, Chicken, Camelids), Molecule (Monoclonal) - Global Forecast to 2030
USD 3.54 BN
MARKET SIZE, 2030
CAGR 13.3%
(2025-2030)
377
REPORT PAGES
410
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The antibody discovery services market is projected to reach USD 3.54 billion in 2030 from USD 1.90 billion in 2025, at a CAGR of 13.3% The antibody discovery services market is influenced by numerous factors. The development of new antibody formats such as bispecific antibodies (0.8>5) and Fab fragments, along with the increasing number of antibody-drug conjugates (ADCs) in clinical trials, continues to broaden discovery activities.
KEY TAKEAWAYS
-
By RegionThe North America antibody discovery services market accounted for a 44.5% revenue share in 2024.
-
By ServiceBy service type, the antibody engineering & optimization segment is expected to dominate the market.
-
By TechnologyBy technology, the single cell technology segment is projected to grow at the fastest rate from 2025 to 2030.
-
By HostBy host, the mouse & rat segment is expected to dominate the market.
-
Key PlayersCompany WuXi Biologics (China), Thermo Fisher Scientific (US), and Charles River Laboratories (US) were identified as some of the star players in the antibody discovery services market (global), given their strong market share and service footprint.
-
SMEsCompanies Abzena (US) and Alloy Therapeutics, Inc. (US), among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders
Rising venture capital and partnership funding support ongoing research and strengthen pipelines in biologics The adoption of end-to-end discovery-to-IND service models and the integration of artificial intelligence and automation enhance efficiency and speed up workflows. At the same time, the high cost and complexity of discovery processes, competition from alternative modalities including cell and gene therapies, and the impact of patent cliffs with the rise of biosimilars influence the operational environment.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The impact on customers’ business in the antibody discovery services market is shaped by faster development cycles and rising complexities in therapeutic modalities. Pharma, biotech, and research institutes are the primary users, with hit-to-lead speed and regulatory-ready data as focus areas. Shifts toward single-cell B-cell workflows, next-gen display libraries, AI/ML-guided engineering, and human-Ig transgenic hosts are redefining how targets are validated and leads are selected. At the same time, tighter quality expectations (early liability screens, orthogonal functional assays, FAIR data packages) and pressure to de-risk late-stage failures directly affect R&D productivity and portfolio value. These factors, in turn, drive demand for integrated discovery partners that bundle antigen design, immunization/host management, engineering, and characterization—shaping the market’s growth trajectory.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Development of bispecific antibodies and antibody fragments.
-
Rising number of antibody-drug conjugates in clinical trials.
RESTRAINTS
Impact
Level
Level
-
High cost and complexity of biologics discovery.
-
Patent cliffs for blockbuster monoclonal antibodies and rise of biosimilars.
OPPORTUNITIES
Impact
Level
Level
-
Integration of AI and automation in discovery workflow.
-
End-to-end discovery–to–IND service bundles/one-stop shop models in antibody discovery.
CHALLENGES
Impact
Level
Level
-
Reagent and raw material supply chain bottlenecks.
-
Fragmented data and disjointed workflow infrastructure.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Development of bispecific antibodies and antibody fragments.
Bispecific antibodies and antibody fragments, such as Fab fragments, have been key drivers in the antibody discovery services market. Unlike traditional monoclonal antibodies that target a single molecule, these innovative formats allow for more precise and adaptable therapeutic applications, especially in cancer treatment. Bispecific antibodies can bind two different targets simultaneously, such as a tumor cell and a T-cell, effectively "retargeting" the immune system to combat cancer. Fab fragments, being smaller and lacking the FC region, offer advantages in tissue penetration and can be used to engineer complex molecules.
Restraint: High cost and complexity of biologics discovery.
The antibody discovery services market is significantly limited by the combined effects of technical complexity and high capital and operating costs. Biologics research requires specialized infrastructure— bioreactors, sterile vial-filling, and cold-chain logistics—and advanced analytical platforms to analyze large, diverse proteins and formulations, which increases capital investment and per-project operational expenses.
Opportunity: Integration of AI and automation in discovery workflow.
The merging of Al and automation in antibody discovery workflows is driving unprecedented efficiency and innovation in the antibody discovery services market For example, (UK) employs machine learning combined with robotics to design, build, and test antibodies with minimal human intervention, achieving rapid lead generation in about six weeks. Creative Biolabs (US) provides Al-based, high- throughput de novo antibody design services that can produce thousands of candidates in just two weeks, incorporating automated wet-lab validation for both quality and speed.
Challenge: Reagent and raw material supply chain bottlenecks.
Reagent and raw material supply bottlenecks significantly constrain the antibody discovery services market. Increasing upstream titers, diverse antibody modalities ADCs, fragments), and expanded clinical pipelines intensify demand for chromatography resins, Protein A ligands, bulk buffers, cell culture media, viral clearance reagents, and single-use disposables. Recent disruptions—like COVID- 19-related factory slowdowns, shipping delays, and regional labor shortages—have led to longer lead times and intermittent stockouts, delaying process development and scale-up.
antibody-discovery-market: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Rapid discovery of SARS-CoV-2 neutralizing antibodies from convalescent patient samples using AbCellera’s single-cell platform; program advanced to bamlanivimab (LY-CoV555) with Lilly. | Speed to clinic via high-throughput single-cell mining and on-platform characterization; therapeutic-grade leads ready for transfer; ability to stand up large discovery campaigns quickly in response to emerging pathogens. |
 |
Multi-target collaboration with Biocytogen using RenMab fully human-Ig mice for in-vivo immunization, discovery, and characterization, with options for development/licensing. | Human-sequence antibodies (reduced re-engineering) with strong developability; higher probability of translation from in-vivo selection; scalable platform across multiple targets under a single master framework. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The antibody discovery services market operates within an interconnected ecosystem comprised of raw material suppliers, service providers, end users, and regulatory agencies. Suppliers deliver essential reagents, consumables, and assay technologies that support high-quality research and development. Service providers offer platform-based services for antibody generation, engineering, preclinical testing, and small-scale manufacturing, helping clients accelerate candidate development. End users, including pharmaceutical and biotechnology companies, rely on these services to expand pipelines, reduce costs, and shorten timelines through outsourcing.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Antibody Services Market, By Service
As of 2024, antibody engineering & optimization segment held the largest share of the antibody discovery services market and will continue leading the market through 2025. This antibody engineering & optimization segment is being accelerated by surging demand for targeted biologics in chronic and infectious diseases, continuous advancements in high-throughput, AI-enabled engineering technologies, and an increasing outsourcing of development to specialized service providers.
Antibody Services Market, By Technology
In 2024, hybridoma technology dominated the antibody engineering & optimization services market. Hybridoma technology remains essential for antibody discovery, providing natural heavy-light chain pairing and in vivo affinity maturation. Recent progress aims to enhance throughput, consistency, and scalability. A 2025 biomedical engineering review highlights how integrating hybridoma workflows with single-cell sequencing and antibody library display greatly speeds up monoclonal antibody production, solving long-standing bottlenecks of traditional fusion and screening.
Antibody Services Market, By Host
The mouse & rat segment is expected to dominate the immunization & host management services market through the forecast period. The mouse & rat segment within the immunization & host management services market focuses on using these rodent species as hosts for producing antibodies. This segment includes services that offer custom antibody development in mice and rats, serving various research and therapeutic purposes. The large share of this segment can be attributed to the growing demand in preclinical research and development of therapeutic antibodies
Antibody Services Market, By Molecule
The monoclonal antibodies segment is expected to dominate the antibody discovery services market through 2025 to 2030. The increase in demand for outsourcing the discovery process in this space is attributed to the rapid expansion of next-generation mAbs, including humanized, fully human, and Fc-engineered formats. Additionally, expanding the clinical pipeline of mAbs across oncology, immunology, and infectious diseases has rendered this segment with the highest growth rate .
Antibody Services Market, By End User
As of 2024, the pharmaceutical & biotechnology companies segment dominated the antibody discovery services market. Factors such as strategic collaborations and agreements with a strong focus on AI-driven antibody discovery services are expected to support the growth of the pharmaceutical & biotechnology companies segment during the forecast period.
REGION
North America to be the largest revenue generating region in the antibody discovery services market during forecast period
North America dominated the antibody discovery services market with the largest share. Key factors driving the antibody discovery services market include advances in formats such as bispecific antibodies (bsAbs) and antibody-drug conjugates (ADCs), along with increased venture funding and collaborative efforts. Additionally, using artificial intelligence and adopting integrated end-to-end service models enhances workflows, boosts efficiency, and supports faster innovation across discovery processes.
antibody-discovery-market: COMPANY EVALUATION MATRIX
In the antibody discovery services key players market matrix, WuXi Biologics (Star) leads with a strong market share and extensive service footprint, supported by its expansive global footprint and ongoing investments in integrated discovery-to-manufacturing platforms. Twist Bioscience (Emerging Leader) is gaining visibility with its specialized solutions and tailored solutions for antibody discovery. The company's expanding its regional presence and caters to several niche service offerings such as VHH antibody discovery, anti-idiotypic antibody discovery, and others.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Charles River Laboratories (US)
- Thermo Fisher Scientific Inc. (US)
- WuXi Biologics (China)
- EVOTEC (Germany)
- Biocytogen (China)
- Aurigene Pharmaceutical Services Ltd. (Dr. Reddy’s Laboratories) (India)
- Sino Biological, Inc. (China)
- Samsung Biologics (South Korea)
- Twist Bioscience (US)
- Curia Global, Inc. (US)
- Danaher Corporation (US)
- GenScript (US)
- ImmunoPrecise Antibodies Ltd. (Canada)
- Aragen Life Sciences Ltd. (India)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 1.68 Billion |
| Market Forecast in 2030 (Value) | USD 3.54 Billion |
| Growth Rate | CAGR of 13.3% from 2025-2030 |
| Years Considered | 2023-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Asia Pacific, Europe, Latin America, Middle East, and Africa |
WHAT IS IN IT FOR YOU: antibody-discovery-market REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Competitive Landscape Analysis | Additional profiles of regional/local players, their market position/share, strategies, and service portfolios | Insights to uncover market gaps and refine differentiation strategies. |
| End User Market Assessment | Comprehensive list of end users typically engaged in discovery, development & manufacturing of biologics (cell therapy, gene therapy) across targeted regions/countries. | Insights on identifying potential customers of antibody discovery services |
| Market Share Analysis and Cross-segmental analysis | Regional market share analysis of antibody discovery services and cross-segmental analysis between services and molecule | Insights on White Spaces & Unmet Needs, interconnections and supply chain opportunities. |
| Qualitative Analysis of Patent Landscape | Patent landscape & IP strength mapping in antibody discovery technologies and Competitive innovations | Information on attractive landscapes within antibody discovery, future applications and new technologies. |
RECENT DEVELOPMENTS
- January 2025 : Charles River Laboratories (US) formed a strategic partnership with NJ Bio (US) to accelerate Antibody-Drug Conjugate (ADC) discovery and development. The alliance combines Charles River’s antibody discovery and characterization services with NJ Bio’s expertise in bioconjugation and GMP manufacturing, offering end-to-end ADC development from early discovery to clinical readiness.
- June 2024 : Thermo Fisher Scientific (US) expanded its clinical research laboratory in Wisconsin. The new 72,500-square-foot building increases the site’s chemistry, manufacturing, and control (CMC) analytical capabilities as part of its clinical development and laboratory services.
- August 2023 : Biocytogen (China) opened its new facility in Waltham, MA. The state-of-the-art facility at 300 Third Avenue will triple Biocytogen Boston’s workspace to include a climate-controlled 4,000-cage vivarium, cell culture, procedure suites, and an open design concept to facilitate collaboration among employees and visiting clients.
- COLUMN 'A' SHOULD BE IN TEXT FORMAT AND NOT DATE FORMAT :
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
35
2
RESEARCH METHODOLOGY
39
3
EXECUTIVE SUMMARY
52
4
PREMIUM INSIGHTS
61
5
MARKET OVERVIEW
Explore booming antibody market dynamics, driven by innovation, despite high costs and competitive pressures.
71
5.1
INTRODUCTION
5.2
MARKET DYNAMICS
5.2.1
DRIVERS
5.2.1.1
DEVELOPMENT OF BISPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS
5.2.1.2
RISING NUMBER OF ANTIBODY-DRUG CONJUGATES IN CLINICAL TRIALS
5.2.1.3
INCREASING VENTURE AND PARTNERSHIP FUNDING FOR BIOLOGICS
5.2.2
RESTRAINTS
5.2.2.1
HIGH COSTS AND COMPLEXITY OF BIOLOGICS DISCOVERY
5.2.2.2
COMPETITION FROM ALTERNATIVE MODALITIES
5.2.2.3
PATENT CLIFFS FOR BLOCKBUSTER MONOCLONAL ANTIBODIES AND RISE OF BIOSIMILARS
5.2.3
OPPORTUNITIES
5.2.3.1
END-TO-END DISCOVERY–TO–IND SERVICE BUNDLES/ONE-STOP SHOP MODELS IN ANTIBODY DISCOVERY
5.2.3.2
INTEGRATION OF AI AND AUTOMATION IN DISCOVERY WORKFLOW
5.2.4
CHALLENGES
5.2.4.1
REAGENTS AND RAW MATERIAL SUPPLY CHAIN BOTTLENECKS
5.2.4.2
FRAGMENTED DATA AND DISJOINTED WORKFLOW INFRASTRUCTURE
6
INDUSTRY TRENDS
Navigate industry disruptions with cutting-edge technologies and strategic investment insights for antibody innovation.
77
6.1
TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
6.2
VALUE CHAIN ANALYSIS
6.3
ECOSYSTEM ANALYSIS
6.3.1
RAW MATERIAL SUPPLIERS
6.3.2
ANTIBODY DISCOVERY SERVICE PROVIDERS
6.3.3
END USERS
6.3.4
REGULATORY BODIES
6.4
INVESTMENT & FUNDING SCENARIO
6.4.1
MAJOR INVESTMENTS AND FUNDING
6.5
TECHNOLOGY ANALYSIS
6.5.1
KEY TECHNOLOGIES
6.5.1.1
PHAGE DISPLAY PLATFORMS
6.5.1.2
HYBRIDOMA TECHNOLOGY
6.5.1.3
SINGLE B-CELL SCREENING
6.5.2
COMPLEMENTARY TECHNOLOGIES
6.5.2.1
AI/ML-BASED PROTEIN STRUCTURE PREDICTION
6.5.2.2
SURFACE PLASMON RESONANCE (SPR)/BIO-LAYER INTERFEROMETRY (BLI)
6.5.2.3
CRYO-ELECTRON MICROSCOPY (CRYO-EM)
6.5.3
ADJACENT TECHNOLOGIES
6.5.3.1
CRISPR-BASED FUNCTIONAL GENOMICS
6.5.3.2
CHO CELL LINE DEVELOPMENT
6.5.3.3
IN-VIVO MODELLING
6.6
PATENT ANALYSIS
6.6.1
METHODOLOGY
6.6.2
NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014−2024
6.6.3
LIST OF KEY PATENTS
6.7
KEY CONFERENCES & EVENTS, 2025–2026
6.8
CASE STUDY ANALYSIS
6.8.1
BISPECIFIC ANTIBODY MANUFACTURABILITY ASSESSMENT AND OPTIMIZATION
6.8.2
ACCELERATING ANTIBODY DISCOVERY FOR PANDEMIC PREPAREDNESS
6.8.3
USE OF REPAB POLYCLONAL ANTIBODY SEQUENCING PLATFORM TO TO IDENTIFY PROTECTIVE ANTIBODIES FROM HUMAN HOSTS IMMUNE TO MALARIA
6.9
REGULATORY ANALYSIS
6.9.1
REGULATORY LANDSCAPE
6.9.1.1
NORTH AMERICA
6.9.1.2
EUROPE
6.9.1.3
ASIA PACIFIC
6.9.1.4
REST OF THE WORLD
6.9.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.10
PORTER’S FIVE FORCES ANALYSIS
6.10.1
BARGAINING POWER OF SUPPLIERS
6.10.2
BARGAINING POWER OF BUYERS
6.10.3
THREAT OF NEW ENTRANTS
6.10.4
THREAT OF SUBSTITUTES
6.10.5
INTENSITY OF COMPETITIVE RIVALRY
6.11
KEY STAKEHOLDERS & BUYING CRITERIA
6.11.1
KEY STAKEHOLDERS IN BUYING PROCESS
6.11.2
KEY BUYING CRITERIA
6.12
IMPACT OF AI/GEN AI ON ANTIBODY DISCOVERY SERVICES MARKET
6.12.1
INTRODUCTION
6.12.2
MARKET POTENTIAL OF AI
7
ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 65 Data Tables
101
7.1
INTRODUCTION
7.2
TARGET IDENTIFICATION & VALIDATION
7.2.1
INTEGRATION OF OMICS-DRIVEN INSIGHTS WITH HIGH-THROUGHPUT FUNCTIONAL VALIDATION TO PROPEL MARKET GROWTH
7.3
ANTIBODY ENGINEERING & OPTIMIZATION
7.3.1
ANTIBODY ENGINEERING & OPTIMIZATION, BY TECHNOLOGY
7.3.1.1
PHAGE DISPLAY TECHNOLOGY
7.3.1.2
HYBRIDOMA TECHNOLOGY
7.3.1.3
SINGLE-CELL TECHNOLOGIES
7.3.1.4
OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES
7.4
ANTIGEN DESIGN & PRODUCTION
7.4.1
HIGH-QUALITY ANTIGEN DESIGN AND PRODUCTION TO SPUR SEGMENT GROWTH
7.5
IMMUNIZATION & HOST MANAGEMENT
7.5.1
RISING ADOPTION OF ADVANCED TRANSGENIC AND HUMANIZED MODELS TO PROPEL SEGMENT GROWTH
7.6
OTHER ANTIBODY DISCOVERY SERVICES
8
IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 36 Data Tables
136
8.1
INTRODUCTION
8.2
MOUSE & RAT
8.2.1
GROWING PRECLINICAL RESEARCH DEMAND TO DRIVE GROWTH
8.3
RABBIT
8.3.1
INCREASED RESEARCH AND DIAGNOSTIC APPLICATIONS TO FAVOR MARKET GROWTH
8.4
CHICKEN
8.4.1
INCREASING FOCUS OF THERAPEUTIC AND DIAGNOSTIC APPLICATIONS TO DRIVE MARKET
8.5
CAMELIDS
8.5.1
RISING ADOPTION OF NANOBODIES IN THERAPEUTICS AND DIAGNOSTICS TO BOOST MARKET GROWTH
8.6
OTHER HOSTS
9
ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 22 Data Tables
155
9.1
INTRODUCTION
9.2
MONOCLONAL ANTIBODIES
9.2.1
GROWING ADOPTION IN TISSUE TYPING FOR ORGAN & BLOOD TRANSPLANTS AND PERSONALIZED MEDICINES TO DRIVE MARKET
9.3
POLYCLONAL ANTIBODIES
9.3.1
DIVERSE EPITOPE RECOGNITION ABILITY OF POLYCLONAL ANTIBODIES TO SUPPORT SEGMENT GROWTH
9.4
OTHER MOLECULES
10
ANTIBODY DISCOVERY SERVICES MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 22 Data Tables
167
10.1
INTRODUCTION
10.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1
STRATEGIC COLLABORATIONS AND AI INTEGRATION TO BOLSTER GROWTH
10.3
ACADEMIC & RESEARCH INSTITUTES
10.3.1
INCREASING COLLABORATIVE RESEARCH AND RISING GRANT FUNDING TO AUGMENT MARKET GROWTH
10.4
OTHER END USERS
11
ANTIBODY DISCOVERY SERVICES MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 16 Countries | 153 Data Tables.
179
11.1
INTRODUCTION
11.2
NORTH AMERICA
11.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2
US
11.2.2.1
US TO DOMINATE ANTIBODY DISCOVERY SERVICES MARKET DURING FORECAST PERIOD
11.2.3
CANADA
11.2.3.1
INNOVATIVE BIOTECH COMMUNITY AND STRATEGIC PLATFORM INVESTMENTS TO PROPEL MARKET GROWTH
11.3
EUROPE
11.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2
GERMANY
11.3.2.1
TRANSFORMATIVE CROSS-BORDER ACQUISITIONS AND PLATFORM-DRIVEN ANTIBODY INNOVATION TO EXPEDITE MARKET GROWTH
11.3.3
UK
11.3.3.1
RAMPED ADC INNOVATION AND SURGING BIOTECH INVESTMENT TO PROPEL MARKET GROWTH
11.3.4
FRANCE
11.3.4.1
STRATEGIC BIOMANUFACTURING INVESTMENTS AND AI-ENABLED INNOVATION TO SUPPORT MARKET EXPANSION
11.3.5
ITALY
11.3.5.1
ADVANCED R&D INFRASTRUCTURE AND BIOTECH INNOVATION TO AID MARKET GROWTH
11.3.6
SPAIN
11.3.6.1
HIGH BIOTECH INVESTMENT AND INNOVATION IN ADVANCED ANTIBODY MODALITIES TO DRIVE MARKET
11.3.7
REST OF EUROPE
11.4
ASIA PACIFIC
11.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2
CHINA
11.4.2.1
SCALABLE INTEGRATED PLATFORMS, STRATEGIC GLOBAL CERTIFICATION, AND DOMESTIC INNOVATION ACCELERATION TO AUGMENT MARKET GROWTH
11.4.3
JAPAN
11.4.3.1
ENHANCED TRANSLATIONAL PLATFORMS AND STRATEGIC CROSS-BORDER R&D PARTNERSHIPS TO EXPEDITE MARKET GROWTH
11.4.4
INDIA
11.4.4.1
ADVANCED BIOMANUFACTURING PLATFORMS AND INNOVATION-LED PUBLIC-PRIVATE PARTNERSHIPS TO STRENGTHEN INDIAN MARKET
11.4.5
SOUTH KOREA
11.4.5.1
AI PLATFORM INVESTMENTS AND CDMO-LED MODALITY INNOVATION TO ACCELERATE MARKET GROWTH
11.4.6
AUSTRALIA
11.4.6.1
HIGH-THROUGHPUT SINGLE-CELL PLATFORMS AND INCREASED ACADEMIC-INDUSTRY COLLABORATIONS TO SPUR MARKET GROWTH
11.4.7
REST OF ASIA PACIFIC
11.5
LATIN AMERICA
11.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2
BRAZIL
11.5.2.1
LOCAL BIOLOGICS INFRASTRUCTURE EXPANSION AND COLLABORATIVE INNOVATION ECOSYSTEMS TO FAVOR MARKET GROWTH
11.5.3
MEXICO
11.5.3.1
FOCUS ON LOCAL EMERGING STARTUPS AND INDUSTRY-ACADEMIC COLLABORATIONS TO AID ANTIBODY DISCOVERY SERVICES
11.5.4
REST OF LATIN AMERICA
11.6
MIDDLE EAST
11.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST
11.6.2
GCC COUNTRIES
11.6.2.1
UAE
11.6.2.2
KINGDOM OF SAUDI ARABIA
11.6.2.3
REST OF GCC COUNTRIES
11.6.3
REST OF MIDDLE EAST
11.7
AFRICA
11.7.1
ADVANCED REGIONAL MANUFACTURING CAPABILITIES AND BIOTECH INNOVATION ECOSYSTEMS TO DRIVE MARKET
11.7.2
MACROECONOMIC OUTLOOK FOR AFRICA
12
COMPETITIVE LANDSCAPE
Discover top strategies and rising stars shaping the antibody discovery services market landscape.
269
12.1
INTRODUCTION
12.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ANTIBODY DISCOVERY SERVICES MARKET
12.3
REVENUE ANALYSIS, 2020–2024
12.4
MARKET SHARE ANALYSIS, 2024
12.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.5.1
STARS
12.5.2
EMERGING LEADERS
12.5.3
PERVASIVE PLAYERS
12.5.4
PARTICIPANTS
12.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.5.5.1
COMPANY FOOTPRINT
12.5.5.2
REGION FOOTPRINT
12.5.5.3
TYPE FOOTPRINT
12.5.5.4
HOST FOOTPRINT
12.5.5.5
MOLECULE FOOTPRINT
12.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.6.1
PROGRESSIVE COMPANIES
12.6.2
RESPONSIVE COMPANIES
12.6.3
DYNAMIC COMPANIES
12.6.4
STARTING BLOCKS
12.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
12.6.5.1
LIST OF KEY STARTUPS/SMES
12.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
12.7
COMPANY VALUATION & FINANCIAL METRICS
12.7.1
FINANCIAL METRICS
12.7.2
COMPANY VALUATION
12.8
BRAND/SERVICE COMPARISON
12.9
COMPETITIVE SCENARIO
12.9.1
SERVICE LAUNCHES
12.9.2
DEALS
12.9.3
EXPANSIONS
13
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
291
13.1
KEY PLAYERS
13.1.1
WUXI BIOLOGICS
13.1.1.1
BUSINESS OVERVIEW
13.1.1.2
SERVICES OFFERED
13.1.1.3
RECENT DEVELOPMENTS
13.1.1.4
MNM VIEW
13.1.2
THERMO FISHER SCIENTIFIC INC.
13.1.3
CHARLES RIVER LABORATORIES
13.1.4
EVOTEC
13.1.5
BIOCYTOGEN
13.1.6
EUROFINS SCIENTIFIC
13.1.7
SHANGHAI CHEMPARTNER
13.1.8
AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY’S LABORATORIES)
13.1.9
SINO BIOLOGICAL, INC.
13.1.10
SAMSUNG BIOLOGICS
13.1.11
GENSCRIPT
13.1.12
CURIA GLOBAL, INC.
13.1.13
TWIST BIOSCIENCE
13.1.14
HARBOUR BIOMED
13.1.15
ARAGEN LIFE SCIENCES LTD.
13.1.16
DANAHER CORPORATION
13.1.17
CREATIVE BIOLABS
13.1.18
VIVA BIOTECH
13.1.19
IMMUNOPRECISE ANTIBODIES LTD.
13.1.20
FUSION ANTIBODIES
13.2
OTHER PLAYERS
13.2.1
ABZENA
13.2.2
ALLOY THERAPEUTICS, INC.
13.2.3
INTEGRAL MOLECULAR
13.2.4
BIODURO
13.2.5
SYNBIO TECHNOLOGIES
13.2.6
ABSOLUTE ANTIBODY
13.2.7
ADIMAB
13.2.8
ISOGENICA
13.2.9
ABLEXIS
13.2.10
FAIRJOURNEY
14
APPENDIX
373
14.1
DISCUSSION GUIDE
14.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3
CUSTOMIZATION OPTIONS
14.4
RELATED REPORTS
14.5
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
ANTIBODY DISCOVERY SERVICES MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2
IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS IN ANTIBODY DISCOVERY SERVICES MARKET
TABLE 3
ANTIBODY DISCOVERY SERVICES MARKET: RISK ANALYSIS
TABLE 4
KEY IP/PLATFORM ASSETS OF KEY PLAYERS, 2022–2025
TABLE 5
IMPACT ANALYSIS OF ANTIBODY DISCOVERY SERVICES MARKET DYNAMICS
TABLE 6
MAJOR VENTURE AND PARTNERSHIP FUNDING FOR BIOLOGICS, 2025
TABLE 7
ROLE OF RAW MATERIAL SUPPLIERS IN ANTIBODY DISCOVERY SERVICES MARKET ECOSYSTEM
TABLE 8
ROLE OF ANTIBODY DISCOVERY SERVICE PROVIDERS IN ANTIBODY DISCOVERY SERVICES MARKET ECOSYSTEM
TABLE 9
ROLE OF END USERS IN ANTIBODY DISCOVERY SERVICES MARKET ECOSYSTEM
TABLE 10
ROLE OF REGULATORY BODIES IN ANTIBODY DISCOVERY SERVICES MARKET ECOSYSTEM
TABLE 11
NUMBER OF PATENTS FILED (APPLIED/GRANTED) IN ANTIBODY DISCOVERY SERVICES MARKET, 2014−2024
TABLE 12
LIST OF KEY PATENTS IN ANTIBODY DISCOVERY SERVICES MARKET
TABLE 13
LIST OF KEY CONFERENCES & EVENTS IN ANTIBODY DISCOVERY SERVICES MARKET, JANUARY 2025–DECEMBER 2026
TABLE 14
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18
ANTIBODY DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES
TABLE 19
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%), BY TYPE
TABLE 20
KEY BUYING CRITERIA FOR MAJOR END USERS
TABLE 21
KEY PLAYERS IMPLEMENTING AI IN ANTIBODY DISCOVERY SERVICES
TABLE 22
ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 23
TARGET IDENTIFICATION & VALIDATION MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 24
NORTH AMERICA: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 25
EUROPE: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 26
ASIA PACIFIC: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 27
LATIN AMERICA: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 28
MIDDLE EAST: TARGET IDENTIFICATION & VALIDATION MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 29
GCC COUNTRIES: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 30
ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 31
NORTH AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 32
EUROPE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 33
ASIA PACIFIC: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 34
LATIN AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 35
MIDDLE EAST: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 36
GCC COUNTRIES: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 37
ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 38
PHAGE DISPLAY TECHNOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 39
NORTH AMERICA: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 40
EUROPE: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 41
ASIA PACIFIC: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 42
LATIN AMERICA: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 43
MIDDLE EAST: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 44
GCC COUNTRIES: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 45
HYBRIDOMA TECHNOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 46
NORTH AMERICA: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 47
EUROPE: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 48
ASIA PACIFIC: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 49
LATIN AMERICA: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 50
MIDDLE EAST: HYBRIDOMA TECHNOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 51
GCC COUNTRIES: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 52
SINGLE-CELL TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 53
NORTH AMERICA: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 54
EUROPE: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 55
ASIA PACIFIC: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 56
LATIN AMERICA: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 57
MIDDLE EAST: SINGLE-CELL TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 58
GCC COUNTRIES: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 59
OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 60
NORTH AMERICA: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 61
EUROPE: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 62
ASIA PACIFIC: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 63
LATIN AMERICA: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 64
MIDDLE EAST: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 65
GCC COUNTRIES: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 66
ANTIGEN DESIGN & PRODUCTION MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 67
NORTH AMERICA: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 68
EUROPE: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 69
ASIA PACIFIC: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 70
LATIN AMERICA: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 71
MIDDLE EAST: ANTIGEN DESIGN & PRODUCTION MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 72
GCC COUNTRIES: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 73
IMMUNIZATION & HOST MANAGEMENT MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 74
NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 75
EUROPE: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 76
ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 77
LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 78
MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 79
GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 80
OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 81
NORTH AMERICA: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 82
EUROPE: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 83
ASIA PACIFIC: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 84
LATIN AMERICA: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 85
MIDDLE EAST: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 86
GCC COUNTRIES: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 87
IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 88
IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY REGION, 2023–2030 (USD MILLION)
TABLE 89
NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 90
EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 91
ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 92
LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 93
MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY REGION, 2023–2030 (USD MILLION)
TABLE 94
GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 95
IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY REGION, 2023–2030 (USD MILLION)
TABLE 96
NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 97
EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 98
ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 99
LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 100
MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY REGION, 2023–2030 (USD MILLION)
TABLE 101
GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 102
IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY REGION, 2023–2030 (USD MILLION)
TABLE 103
NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 104
EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 105
ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 106
LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 107
MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY REGION, 2023–2030 (USD MILLION)
TABLE 108
GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 109
IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY REGION, 2023–2030 (USD MILLION)
TABLE 110
NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 111
EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 112
ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 113
LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 114
MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY REGION, 2023–2030 (USD MILLION)
TABLE 115
GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 116
IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 117
NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 118
EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 119
ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 120
LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 121
MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 122
GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 123
ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 124
ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 125
NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 126
EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 127
ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 128
LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 129
MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 130
GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 131
ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 132
NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 133
EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 134
ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 135
LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 136
MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 137
GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 138
ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION)
TABLE 139
NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 140
EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 141
ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 142
LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 143
MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION)
TABLE 144
GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 145
ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 146
ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 147
NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 148
EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 149
ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 150
LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 151
MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 152
GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 153
ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
TABLE 154
NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 155
EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 156
ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 157
LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 158
MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 159
GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 160
ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 161
NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 162
EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 163
ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 164
LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 165
MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 166
GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 167
ANTIBODY DISCOVERY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 168
NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 169
NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 170
NORTH AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 171
NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 172
NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 173
NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 174
NORTH AMERICA: KEY MACROINDICATORS
TABLE 175
US: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 176
US: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 177
US: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 178
US: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 179
US: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 180
CANADA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 181
CANADA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 182
CANADA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 183
CANADA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 184
CANADA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 185
EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 186
EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 187
EUROPE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 188
EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 189
EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 190
EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 191
EUROPE: KEY MACROINDICATORS
TABLE 192
GERMANY: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 193
GERMANY: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 194
GERMANY: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 195
GERMANY: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 196
GERMANY: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 197
UK: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 198
UK: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 199
UK: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 200
UK: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 201
UK: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 202
FRANCE: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 203
FRANCE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 204
FRANCE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 205
FRANCE: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 206
FRANCE: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 207
ITALY: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 208
ITALY: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 209
ITALY: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 210
ITALY: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 211
ITALY: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 212
SPAIN: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 213
SPAIN: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 214
SPAIN: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 215
SPAIN: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 216
SPAIN: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 217
REST OF EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 218
REST OF EUROPE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 219
REST OF EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 220
REST OF EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 221
REST OF EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 222
ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 223
ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 224
ASIA PACIFIC: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 225
ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 226
ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 227
ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 228
ASIA PACIFIC: KEY MACROINDICATORS
TABLE 229
CHINA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 230
CHINA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 231
CHINA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 232
CHINA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 233
CHINA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 234
JAPAN: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 235
JAPAN: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 236
JAPAN: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 237
JAPAN: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 238
JAPAN: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 239
INDIA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 240
INDIA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 241
INDIA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 242
INDIA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 243
INDIA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 244
SOUTH KOREA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 245
SOUTH KOREA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 246
SOUTH KOREA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 247
SOUTH KOREA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 248
SOUTH KOREA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 249
AUSTRALIA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 250
AUSTRALIA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 251
AUSTRALIA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 252
AUSTRALIA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 253
AUSTRALIA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 254
REST OF ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 255
REST OF ASIA PACIFIC: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 256
REST OF ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 257
REST OF ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 258
REST OF ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 259
LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 260
LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 261
LATIN AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 262
LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 263
LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 264
LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 265
LATIN AMERICA: KEY MACROINDICATORS
TABLE 266
BRAZIL: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 267
BRAZIL: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 268
BRAZIL: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 269
BRAZIL: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 270
BRAZIL: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 271
MEXICO: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 272
MEXICO: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 273
MEXICO: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 274
MEXICO: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 275
MEXICO: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 276
REST OF LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 277
REST OF LATIN AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 278
REST OF LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 279
REST OF LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 280
REST OF LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 281
MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 282
MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 283
MIDDLE EAST: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 284
MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 285
MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 286
MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 287
MIDDLE EAST: KEY MACROINDICATORS
TABLE 288
GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 289
GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 290
GCC COUNTRIES: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 291
GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 292
GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 293
GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 294
UAE: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 295
UAE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 296
UAE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 297
UAE: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 298
UAE: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 299
KINGDOM OF SAUDI ARABIA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 300
KINGDOM OF SAUDI ARABIA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 301
KINGDOM OF SAUDI ARABIA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 302
KINGDOM OF SAUDI ARABIA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 303
KINGDOM OF SAUDI ARABIA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 304
REST OF GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 305
REST OF GCC COUNTRIES: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 306
REST OF GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 307
REST OF GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 308
REST OF GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 309
REST OF MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 310
REST OF MIDDLE EAST: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 311
REST OF MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 312
REST OF MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 313
REST OF MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 314
AFRICA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 315
AFRICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 316
AFRICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 317
AFRICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 318
AFRICA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 319
AFRICA: KEY MACROINDICATORS
TABLE 320
OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN ANTIBODY DISCOVERY SERVICES MARKET, JANUARY 2022–AUGUST 2025
TABLE 321
ANTIBODY DISCOVERY SERVICES MARKET: DEGREE OF COMPETITION
TABLE 322
ANTIBODY DISCOVERY SERVICES MARKET: REGION FOOTPRINT
TABLE 323
ANTIBODY DISCOVERY SERVICES MARKET: TYPE FOOTPRINT
TABLE 324
ANTIBODY DISCOVERY SERVICES MARKET: HOST FOOTPRINT
TABLE 325
ANTIBODY DISCOVERY SERVICES MARKET: MOLECULE FOOTPRINT
TABLE 326
ANTIBODY DISCOVERY SERVICES MARKET: LIST OF KEY STARTUPS/SME PLAYERS
TABLE 327
ANTIBODY DISCOVERY SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY TYPE AND REGION
TABLE 328
ANTIBODY DISCOVERY SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2022–AUGUST 2025
TABLE 329
ANTIBODY DISCOVERY SERVICES MARKET: DEALS, JANUARY 2022–AUGUST 2025
TABLE 330
ANTIBODY DISCOVERY SERVICES MARKET: EXPANSIONS, JANUARY 2022–AUGUST 2025
TABLE 331
WUXI BIOLOGICS: COMPANY OVERVIEW
TABLE 332
WUXI BIOLOGICS: SERVICES OFFERED
TABLE 333
WUXI BIOLOGICS: DEALS, JANUARY 2022–AUGUST 2025
TABLE 334
WUXI BIOLOGICS: EXPANSIONS, JANUARY 2022–AUGUST 2025
TABLE 335
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 336
THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED
TABLE 337
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–AUGUST 2025
TABLE 338
THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–AUGUST 2025
TABLE 339
CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
TABLE 340
CHARLES RIVER LABORATORIES: SERVICES OFFERED
TABLE 341
CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022–AUGUST 2025
TABLE 342
EVOTEC: COMPANY OVERVIEW
TABLE 343
EVOTEC: SERVICES OFFERED
TABLE 344
EVOTEC: DEALS, JANUARY 2022–AUGUST 2025
TABLE 345
EVOTEC: CONTRACTS, JANUARY 2022–AUGUST 2025
TABLE 346
EVOTEC: EXPANSIONS, JANUARY 2022–AUGUST 2025
TABLE 347
EVOTEC: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025
TABLE 348
BIOCYTOGEN: COMPANY OVERVIEW
TABLE 349
BIOCYTOGEN: SERVICES OFFERED
TABLE 350
BIOCYTOGEN: SERVICE LAUNCHES, JANUARY 2022−AUGUST 2025
TABLE 351
BIOCYTOGEN: DEALS, JANUARY 2022–AUGUST 2025
TABLE 352
BIOCYTOGEN: EXPANSIONS, JANUARY 2022–AUGUST 2025
TABLE 353
EUROFINS SCIENTIFIC: COMPANY OVERVIEW
TABLE 354
EUROFINS SCIENTIFIC: SERVICES OFFERED
TABLE 355
EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2022–AUGUST 2025
TABLE 356
SHANGHAI CHEMPARTNER: COMPANY OVERVIEW
TABLE 357
SHANGHAI CHEMPARTNER: SERVICES OFFERED
TABLE 358
SHANGHAI CHEMPARTNER: DEALS, JANUARY 2022–AUGUST 2025
TABLE 359
AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY’S LABORATORIES): COMPANY OVERVIEW
TABLE 360
AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY’S LABORATORIES): SERVICES OFFERED
TABLE 361
AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY’S LABORATORIES): EXPANSIONS, JANUARY 2022–AUGUST 2025
TABLE 362
SINO BIOLOGICAL, INC.: COMPANY OVERVIEW
TABLE 363
SINO BIOLOGICAL, INC.: SERVICES OFFERED
TABLE 364
SINO BIOLOGICAL, INC.: DEALS, JANUARY 2022–AUGUST 2025
TABLE 365
SINO BIOLOGICAL, INC.: EXPANSIONS, JANUARY 2022–AUGUST 2025
TABLE 366
SAMSUNG BIOLOGICS: COMPANY OVERVIEW
TABLE 367
SAMSUNG BIOLOGICS: SERVICES OFFERED
TABLE 368
SAMSUNG BIOLOGICS: SERVICE LAUNCHES, JANUARY 2022–AUGUST 2025
TABLE 369
GENSCRIPT: COMPANY OVERVIEW
TABLE 370
GENSCRIPT: SERVICES OFFERED
TABLE 371
GENSCRIPT: SERVICE LAUNCHES, JANUARY 2022–AUGUST 2025
TABLE 372
GENSCRIPT: DEALS, JANUARY 2022–AUGUST 2025
TABLE 373
CURIA GLOBAL, INC.: COMPANY OVERVIEW
TABLE 374
CURIA GLOBAL, INC.: SERVICES OFFERED
TABLE 375
CURIA GLOBAL, INC.: DEALS, JANUARY 2022–AUGUST 2025
TABLE 376
CURIA GLOBAL, INC.: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025
TABLE 377
TWIST BIOSCIENCE: COMPANY OVERVIEW
TABLE 378
TWIST BIOSCIENCE: SERVICES OFFERED
TABLE 379
TWIST BIOSCIENCE: SERVICE LAUNCHES, JANUARY 2022–AUGUST 2025
TABLE 380
TWIST BIOSCIENCE: DEALS, JANUARY 2022−AUGUST 2025
TABLE 381
TWIST BIOSCIENCE: EXPANSIONS, JANUARY 2022–AUGUST 2025
TABLE 382
HARBOUR BIOMED: COMPANY OVERVIEW
TABLE 383
HARBOUR BIOMED: SERVICES OFFERED
TABLE 384
HARBOUR BIOMED: DEALS, JANUARY 2022−AUGUST 2025
TABLE 385
HARBOUR BIOMED: OTHER DEVELOPMENTS, JANUARY 2022−AUGUST 2025
TABLE 386
ARAGEN LIFE SCIENCES LTD.: COMPANY OVERVIEW
TABLE 387
ARAGEN LIFE SCIENCES LTD.: SERVICES OFFERED
TABLE 388
ARAGEN LIFE SCIENCES LTD.: EXPANSIONS, JANUARY 2022–AUGUST 2025
TABLE 389
DANAHER CORPORATION: COMPANY OVERVIEW
TABLE 390
DANAHER CORPORATION: SERVICES OFFERED
TABLE 391
DANAHER CORPORATION: DEALS, JANUARY 2022–AUGUST 2025
TABLE 392
CREATIVE BIOLABS: COMPANY OVERVIEW
TABLE 393
CREATIVE BIOLABS: SERVICES OFFERED
TABLE 394
VIVA BIOTECH: COMPANY OVERVIEW
TABLE 395
VIVA BIOTECH: SERVICES OFFERED
TABLE 396
IMMUNOPRECISE ANTIBODIES LTD.: COMPANY OVERVIEW
TABLE 397
IMMUNOPRECISE ANTIBODIES LTD.: SERVICES OFFERED
TABLE 398
IMMUNOPRECISE ANTIBODIES LTD.: DEALS, JANUARY 2022−AUGUST 2025
TABLE 399
FUSION ANTIBODIES: COMPANY OVERVIEW
TABLE 400
FUSION ANTIBODIES: SERVICES OFFERED
TABLE 401
ABZENA: COMPANY OVERVIEW
TABLE 402
ALLOY THERAPEUTICS, INC.: COMPANY OVERVIEW
TABLE 403
INTEGRAL MOLECULAR: COMPANY OVERVIEW
TABLE 404
BIODURO: COMPANY OVERVIEW
TABLE 405
SYNBIO TECHNOLOGIES: COMPANY OVERVIEW
TABLE 406
ABSOLUTE ANTIBODY: COMPANY OVERVIEW
TABLE 407
ADIMAB: COMPANY OVERVIEW
TABLE 408
ISOGENICA: COMPANY OVERVIEW
TABLE 409
ABLEXIS: COMPANY OVERVIEW
TABLE 410
FAIRJOURNEY: COMPANY OVERVIEW
LIST OF FIGURES
FIGURE 1
ANTIBODY DISCOVERY SERVICES MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2
ANTIBODY DISCOVERY SERVICES MARKET: YEARS CONSIDERED
FIGURE 3
ANTIBODY DISCOVERY SERVICES MARKET: RESEARCH DESIGN
FIGURE 4
ANTIBODY DISCOVERY SERVICES MARKET: BREAKDOWN OF PRIMARIES (SUPPLY- AND DEMAND-SIDE PARTICIPANTS)
FIGURE 5
ANTIBODY DISCOVERY SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
FIGURE 6
COMPANY REVENUE ANALYSIS-BASED MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 7
REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC (US), 2024
FIGURE 8
ANTIBODY DISCOVERY SERVICES MARKET SIZE VALIDATION FROM PRIMARY EXPERTS
FIGURE 9
ANTIBODY DISCOVERY SERVICES MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 10
ANTIBODY DISCOVERY SERVICES MARKET: CAGR PROJECTIONS
FIGURE 11
ANTIBODY DISCOVERY SERVICES MARKET: DATA TRIANGULATION METHODOLOGY
FIGURE 12
ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
FIGURE 13
ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
FIGURE 14
IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2025 VS. 2030 (USD MILLION)
FIGURE 15
ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2025 VS. 2030 (USD MILLION)
FIGURE 16
ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 17
ANTIBODY DISCOVERY SERVICES MARKET: REGIONAL SNAPSHOT
FIGURE 18
SNAPSHOT: GLOBAL ANTIBODY DISCOVERY SERVICES MARKET SIZE, GROWTH RATE, AND FORECAST (USD MILLION)
FIGURE 19
INCREASING VENTURE FUNDING AND INVESTMENTS TO DRIVE MARKET
FIGURE 20
US AND MONOCLONAL ANTIBODIES COMMANDED LARGEST NORTH AMERICAN MARKET SHARE IN 2024
FIGURE 21
MONOCLONAL ANTIBODIES TO ACCOUNT FOR LARGEST MARKET SHARE THROUGHOUT FORECAST PERIOD
FIGURE 22
CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030
FIGURE 23
ANTIBODY ENGINEERING & OPTIMIZATION SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2024
FIGURE 24
ANTIBODY DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 25
ANTIBODY DISCOVERY SERVICES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
FIGURE 26
ANTIBODY DISCOVERY SERVICES MARKET: VALUE CHAIN ANALYSIS
FIGURE 27
ANTIBODY DISCOVERY SERVICES MARKET: ECOSYSTEM ANALYSIS
FIGURE 28
NIH FUNDING FOR ANTIBODY DISCOVERY, 2014–2025 (USD MILLION)
FIGURE 29
TOP PATENT APPLICANTS/OWNERS AND NUMBER OF PATENTS GRANTED IN ANTIBODY DISCOVERY SERVICES MARKET, JANUARY 2014–DECEMBER 2024
FIGURE 30
ANTIBODY DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 31
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY TYPE
FIGURE 32
KEY BUYING CRITERIA FOR MAJOR END USERS
FIGURE 33
IMPACT OF AI/GEN AI ON ANTIBODY DISCOVERY SERVICES MARKET
FIGURE 34
NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET SNAPSHOT
FIGURE 35
ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET SNAPSHOT
FIGURE 36
REVENUE ANALYSIS OF KEY PLAYERS IN ANTIBODY DISCOVERY SERVICES MARKET, 2020–2024 (USD MILLION)
FIGURE 37
MARKET SHARE ANALYSIS OF KEY PLAYERS IN ANTIBODY DISCOVERY SERVICES MARKET (2024)
FIGURE 38
ANTIBODY DISCOVERY SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 39
ANTIBODY DISCOVERY SERVICES MARKET: COMPANY FOOTPRINT
FIGURE 40
ANTIBODY DISCOVERY SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 41
EV/EBITDA OF KEY PLAYERS
FIGURE 42
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY PLAYERS
FIGURE 43
ANTIBODY DISCOVERY SERVICES MARKET: BRAND/SERVICE COMPARATIVE ANALYSIS
FIGURE 44
WUXI BIOLOGICS: COMPANY SNAPSHOT
FIGURE 45
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
FIGURE 46
CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
FIGURE 47
EVOTEC: COMPANY SNAPSHOT
FIGURE 48
BIOCYTOGEN: COMPANY SNAPSHOT
FIGURE 49
EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
FIGURE 50
AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY’S LABORATORIES): COMPANY SNAPSHOT
FIGURE 51
SINO BIOLOGICAL, INC.: COMPANY SNAPSHOT
FIGURE 52
SAMSUNG BIOLOGICS: COMPANY SNAPSHOT
FIGURE 53
GENSCRIPT: COMPANY SNAPSHOT
FIGURE 54
TWIST BIOSCIENCE: COMPANY SNAPSHOT
FIGURE 55
HARBOUR BIOMED: COMPANY SNAPSHOT
FIGURE 56
ARAGEN LIFE SCIENCES LTD.: COMPANY SNAPSHOT
FIGURE 57
DANAHER CORPORATION: COMPANY SNAPSHOT
FIGURE 58
VIVA BIOTECH: COMPANY SNAPSHOT
FIGURE 59
IMMUNOPRECISE ANTIBODIES LTD.: COMPANY SNAPSHOT
FIGURE 60
FUSION ANTIBODIES: COMPANY SNAPSHOT
Methodology
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global antibody discovery services market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used primarily to identify & collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Organisation for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), Food and Drug Administration (FDA), ClinicalTrials.gov, Annual Reports, SEC Filings, Investor Presentations, Research Journals, Press Releases, and financial statements. These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative & quantitative information and assess the prospects of the market. Various primary sources from both the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the antibody discovery services market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
The total market was split into several segments and subsegments after arriving at the overall market size from the estimation process. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
The antibody discovery services market involves the use of specialized technologies and platforms to identify, engineer, validate, and optimize antibodies for therapeutic and diagnostic applications. These services support the development of antibody-based solutions targeting a wide range of conditions, including cancer, infectious diseases, autoimmune disorders, and metabolic diseases. Antibody discovery services are classified into different types, including target identification & validation, antibody engineering & optimization (such as phage/yeast display, hybridoma, single-cell technologies, and other technologies), antigen design & production, immunization & host management, and antibody characterization & specificity analysis. Host systems used in antibody generation include mice, rats, rabbits, chickens, camelids, and others (human ex vivo cells, bovine, and more), each providing unique immune repertoires for antibody development. By molecule type, services cover monoclonal antibodies, polyclonal antibodies, and other formats such as bispecific antibodies and nanobodies. These offerings enable efficient antibody generation, high-throughput screening, and optimization to accelerate preclinical and clinical research. Key end users of antibody discovery services include pharmaceutical & biotechnology companies, academic & research institutes, hospitals, and diagnostic laboratories, which rely on outsourcing for enhanced efficiency, reduced development timelines, and access to advanced discovery platforms.
The study provides an in-depth analysis of the antibody discovery services market based on contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key antibody discovery services providers.
Stakeholders
- Manufacturers and Distributors of Antibody Discovery Service Products
- Third-party Suppliers of antibody discovery services Products
- Contract Research Organizations
- Market Research and Consulting Firms
- R&D Centers and Institutes
- Hospitals and Clinics
- Academic Institutions
- Diagnostic Laboratories
Report Objectives
- To define, describe, and forecast the antibody discovery services market based on type, host, molecule, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall antibody discovery services market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the antibody discovery services market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as service launches, acquisitions, expansions, agreements, partnerships, and collaborations in the antibody discovery services market
- To benchmark players within the antibody discovery services market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
Fact checked
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Antibody Discovery Services Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in Antibody Discovery Services Market